Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
7
×
national blog main
national top stories
boston blog main
boston top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
crispr
detroit blog main
detroit top stories
glaxosmithkline
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
crispr therapeutics
fda
gene therapy
indiana blog main
indiana top stories
roche
biogen
cancer
clinical trials
crispr-cas9
deals
editas medicine
eli lilly
What
crispr
7
×
bio
roundup
new
cancer
cas
ceo
gene
known
medicine
therapeutics
today
access
acquisitions
advanced
albert
alliance
allogene
big
biggest
biopharma
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
capacity
car
cell
cells
changing
color
company
congress
congressional
consolidation
crime
Language
unset
unknown
Current search:
national
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells